Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.

Companies / Third Arc Bio, Inc.

Third Arc Bio, Inc.

Series ALower Gwynedd, PAthirdarcbio.comBiotechnology
Facts
Year of incorporation
2021sec.gov
Revenue range (Form D)
Decline to Disclosesec.gov
Rounds on record
2
Disclosed raised
$52.0Msum of rounds with a disclosed amount only
Named investors
2
Financing history
2 rounds
  1. Feb 4, 2026
    Series A Extension · $52.0M (disclosed)
    Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) · “Third Arc Bio Announces $52M Series A Extension to Expand Oncology and Immunology & Inflammation Portfolio”
  2. Jul 16, 2024
    Form D equity offering · $72.5M (form d sold) · 32 investors
    Fact SEC EDGAR Form D data sets (quarterly) · “Third Arc Bio, Inc. filed Form D: $72,499,974 sold of $164,999,939, Biotechnology”
Investors on record
2 edges
People
2 officers, 4 directors
Timeline
3
  1. Sep 16, 2026
    Third Arc Bio, Inc. no longer listed on Omega Fund Management, LLC's portfolio page
    Removed from portfolio page Inference Venture organization websites (about, team, portfolio, thesis, news pages)
  2. Feb 4, 2026
    Third Arc Bio announced Series A Extension of $52,000,000
    Round announced Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS)
  3. Aug 1, 2024
    Third Arc Bio, Inc. filed Form D: $72,499,974 sold of $164,999,939, Biotechnology
    Form D filed Fact SEC EDGAR Form D data sets (quarterly)
Evidence
17 observations
Every observation on this company